LONGER-TERM FOLLOW-UP OF A PHASE 1 STUDY OF PONATINIB IN PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) LEUKEMIAS

被引：0

作者：

Cortes, J. ^{[1
]}

Talpaz, M. ^{[2
]}

Kantarjian, H. M. ^{[1
]}

Shah, N. P. ^{[3
]}

Bixby, D. ^{[2
]}

Flinn, I. W. ^{[4
]}

O'Hare, T. ^{[5
]}

Hu, S. ^{[6
]}

Rivera, V. ^{[6
]}

Clackson, T. ^{[6
]}

Turner, C. ^{[6
]}

Haluska, F. ^{[6
]}

Druker, B. J. ^{[7
]}

Deininger, M. W. ^{[5
]}

Mauro, M. J. ^{[7
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[3] Univ Calif San Francisco, San Francisco, CA 94143 USA

[4] Sarah Cannon Res Inst, Nashville, TN USA

[5] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[6] ARIAD Pharmaceut Inc, Cambridge, MA USA

[7] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

来源：

HAEMATOLOGICA | 2014年 / 99卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P895

引用

页码：335 / 335

页数：1

共 50 条

[1] Longer-term follow up of a phase I study of ponatinib in patients (pts) with Philadelphia chromosome-positive (Ph plus ) leukemias.
Talpaz, Moshe
Cortes, Jorge E.
Kantarjian, Hagop M.
Shah, Neil P.
Bixby, Dale L.
Flinn, Ian
O'Hare, Thomas
Hu, Simin
Rivera, Victor M.
Clackson, Tim
Turner, Christopher D.
Haluska, Frank G.
Drucker, Brian J.
Deininger, Michael W. N.
Mauro, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[2] Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph plus ) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial.
Kantarjian, Hagop M.
Kim, Dong-Wook
Pinilla-Ibaz, Javier
Le Coutre, Philipp D.
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane
Khoury, Hanna Jean
Talpaz, Moshe
DiPersio, John F.
Baccarani, Michele
Lustgarten, Stephanie
Haluska, Frank G.
Guilhot, Francois
Deininger, Michael W. N.
Hochhaus, Andreas
Hughes, Timothy P.
Shah, Neil P.
Cortes, Jorge E.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[3] Safety and Durability of Ponatinib in Patients With Philadelphia Chromosome-Positive (Ph plus ) Leukemia: Long-term Follow-up of an Ongoing Phase 1 Study
Mauro, Michael J.
Cortes, Jorge E.
Kantarjian, Hagop M.
Shah, Neil P.
Bixby, Dale
Flinn, Ian W.
O'Hare, Thomas
Hu, Simin
Rivera, Victor M.
Clackson, Tim
Turner, Christopher D.
Haluska, Frank G.
Druker, Brian J.
Deininger, Michael W.
Talpaz, Moshe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 : S137 - S138
[4] SAFETY AND DURABILITY OF PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) LEUKEMIA: LONG-TERM FOLLOW-UP OF AN ONGOING PHASE 1 STUDY
Mauro, M.
Cortes, J.
Kantarjian, H.
Shah, N.
Bixby, D.
Flinn, I.
O'Hare, T.
Hu, S.
Rivera, V.
Clackson, T.
Turner, C.
Haluska, F.
Druker, B.
Deininger, Mi
Talpaz, M.
HAEMATOLOGICA, 2013, 98 : 295 - 296
[5] PONATINIB IN PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME- POSITIVE (PH plus ) LEUKEMIAS RESISTANT OR INTOLERANT TO DASATINIB OR NILOTINIB, OR WITH THE T315I MUTATION: LONGER-TERM FOLLOW-UP OF THE PACE TRIAL
le Coutre, P. D.
Kim, D. W.
Pinilla-Ibarz, J.
Paquette, R.
Chuah, C.
Nicolini, F. E.
Apperley, J. F.
Khoury, H. J.
Talpaz, M.
DiPersio, J. F.
DeAngelo, D.
Abruzzese, E.
Rea, D.
Baccarani, M.
Muller, M.
Gambacorti-Passerini, C.
Lustgarten, S.
Haluska, F. G.
Guilhot, F.
Deininger, M. W.
Hochhaus, A.
Hughes, T. P.
Shah, N. P.
Kantarjian, H. M.
Cortes, J. E.
HAEMATOLOGICA, 2014, 99 : 334 - 334
[6] Safety and durability of ponatinib in patients with Philadelphia chromosome-positive (Ph plus ) leukemia: Long-term follow-up of an ongoing phase I study
Mauro, Michael J.
Cortes, Jorge E.
Kantarjian, Hagop M.
Shah, Neil P.
Bixby, Dale
Flinn, Ian
O'Hare, Thomas
Hu, Simin
Rivera, Victor M.
Clackson, Tim
Turner, Christopher D.
Haluska, Frank G.
Druker, Brian J.
Deininger, Michael W. N.
Talpaz, Moshe
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[7] CLINICAL IMPACT OF DOSE MODIFICATION AND DOSE INTENSITY ON RESPONSE TO PONATINIB IN PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) LEUKEMIAS
Nicolini, F. E.
Cortes, J. E.
Kim, D. W.
Pinilla-Ibarz, J.
le Coutre, P. D.
Paquette, R.
Chuah, C.
Apperley, J. F.
Khoury, H. J.
Talpaz, M.
DiPersio, J. F.
DeAngelo, D. J.
Abruzzese, E.
Rea, D.
Baccarani, M.
Muller, M. C.
Gambacorti-Passerini, C.
Lustgarten, S.
Rivera, V. M.
Haluska, F. G.
Guilhot, F.
Deininger, M. W.
Hughes, T. P.
Shah, N. P.
Kantarjian, H. M.
Hochhaus, A.
HAEMATOLOGICA, 2014, 99 : 334 - 334
[8] A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias
Cortes, J. E.
Kim, D. -W.
Pinilla-Ibarz, J.
le Coutre, P.
Paquette, R.
Chuah, C.
Nicolini, F. E.
Apperley, J. F.
Khoury, H. J.
Talpaz, M.
DiPersio, J.
DeAngelo, D. J.
Abruzzese, E.
Rea, D.
Baccarani, M.
Mueller, M. C.
Gambacorti-Passerini, C.
Wong, S.
Lustgarten, S.
Rivera, V. M.
Clackson, T.
Turner, C. D.
Haluska, F. G.
Guilhot, F.
Deininger, M. W.
Hochhaus, A.
Hughes, T.
Goldman, J. M.
Shah, N. P.
Kantarjian, H.
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (19) : 1783 - 1796
[9] Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph plus ) leukemias.
Hochhaus, Andreas
Pinilla-Ibarz, Javier
Kim, Dong-Wook
Le Coutre, Philipp D.
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane
Khoury, Hanna Jean
Baccarani, Michele
Lustgarten, Stephanie
Rivera, Victor M.
Haluska, Frank G.
Guilhot, Francois
Deininger, Michael W. N.
Hughes, Timothy P.
Shah, Neil P.
Kantarjian, Hagop M.
Talpaz, Moshe
Cortes, Jorge E.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[10] IMPACT OF BASELINE MUTATIONS ON RESPONSE TO PONATINIB AND END OF TREATMENT MUTATION ANALYSIS IN PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ( PH plus ) LEUKEMIAS
Hughes, T.
Cortese, J.
Kim, D.
Nicolini, F.
Talpaz, M.
Baccarani, M.
Mueller, M.
Lustgarten, S.
Rivera, V.
Clackson, T.
Turner, C.
Haluska, F.
Guilhot, F.
Hochhaus, A.
Goldman, J.
Shah, N.
Kantarjian, H.
Deininger, M.
HAEMATOLOGICA, 2013, 98 : 57 - 57

← 1 2 3 4 5 →